As of the end of the first half, it was found that 30 listed pharmaceutical companies (based on the company that announces its final results for the year ended December) had more than KRW 100 billion in retained earnings. On the other hand, six pharmaceutical companies’ losses exceeded KRW 10 billion.
The combined amount of retained earnings at the end of the first half was KRW 9.4726 trillion, up nearly KRW 150 billion from the end of last year, according to semi-annual reports of listed pharmaceutical companies compiled by Newsmp.
Among the 62 companies surveyed, 38 companies’ retained earnings expanded from last year, while 24 companies decreased.
By company, Chong Kun Dang Pharmaceutical’s retained earnings increased by KRW 27.1 billion, Yuhan Corporation by KRW 26.7 billion, and Celltrion Pharm by more than KRW 20 billion.
Retained earnings of Dongkook Pharmaceutical, Boryung Pharmaceutical, DONGSUNG BIO PHARM, WhanIn Pharm, Huons, and KOREA UNITED PHARM. also increased by more than KRW 10 billion from the end of last year.
On the other hand, over the same period, JW Shinyak’s loss grew by more than KRW 15 billion, and Daewoong Pharmaceutical’s retained earnings decreased by more than KRW 15 billion.
As of the end of the year’s first half, Yuhan Corporation was the only company to exceed KRW 1 trillion in retained earnings by KRW 1.6374 trillion, followed by GC Pharma with KRW 755.7 billion.
Daewoong Pharmaceutical maintained the KRW 400 billion mark with KRW 456.4 billion, Kwang Dong Pharmaceutical approached KRW 400 billion with KRW 399.8 billion, and ILSUNG Pharmaceuticals withdrew from the KRW 400 billion mark with KRW 398.8 billion
Dongkook Pharmaceutical and Boryung Pharmaceutical reported retained earnings of KRW 382.6 billion and KRW 313.6 billion.
Chong Kun Dang Pharmaceutical, HANDOK, WhanIn Pharm, Bukwang Pharm., KOREA UNITED PHARM., DONGWHA PHARM, Kyung Dong Pharm., Samjin Pharmaceutical, and Reyon Pharm. were counted at KRW 200 billion mark.
Moreover, retained earnings of DAEWON Pharm., DAI HAN PHARM., Huons, Dong-A ST, Hanmi Pharmaceutical, HK inno.N, SAMA Pharm Co., Shin Poong Pharm., Hana Pharmaceutical, CKD Bio, Ahngook Pharmaceuticals, ST Pharm, Sinil Pharm., and Kyongbo Pharmaceutical exceeded KRW 100 billion.
At the same time, Aprogen Pharmaceuticals reported a loss of KRW 38.6 billion, Samsung Pharm. KRW 34.7 billion, Myungmoon Pharm. KRW 31.5 billion, CHO-A PHARM. KRW 21.4 billion, JW Shinyak KRW 17.3 billion, SEOUL PHARMACEUTICALS KRW 14.6 billion, and Kyung Nam Pharm. KRW 1.6 billion.
DONGSUNG BIO PHARM shed KRW 11 billion in losses and reported KRW 1.3 billion in retained earnings.
